medinfoАктуальные проблемы теоретической и клинической медициныActual Problems of Theoretical and Clinical Medicine2790-12892790-1297Казахстанско-Российский медицинский университет10.24412/2790-1289-2021-33941medinfo-44Research ArticleОБЗОР ЛИТЕРАТУРЫREVEWSИНГИБИТОРЫ ПРОТОННОЙ ПОМПЫ (ИПП) КАК ФАКТОРЫ ПОВЫШЕННОГО РИСКА ЗАРАЖЕНИЯ КОРОНАВИРУСНОЙ ИНФЕКЦИИ COVID-19 (SARS COV-2) (ОБЗОР)PROTON PUMP INHIBITORS (PPIs) AS FACTORS OF INCREASED RISK OF COVID-19 CORONAVIRAL INFECTION (review)ЖангабыловА. К.ZhangabylovA. K.

д.м.н., профессор

MD, Professor

ТастемироваК. К.TastemirovaK. K.

к.м.н.

Candidate of Medical Sciences

КудабаеваВ. Ж.KudabaevaV. Zh.

врач терапевт

therapist

НУО «Казахстанско-Российский Медицинский Университет»КазахстанNEI «Kazakh-Russian Medical University»Kazakhstan202117102022033941Copyright © Жангабылов А.К., Тастемирова К.К., Кудабаева В.Ж., 20222022Жангабылов А.К., Тастемирова К.К., Кудабаева В.Ж.Zhangabylov A.K., Tastemirova K.K., Kudabaeva V.Z.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://kazrosmedjournal.krmu.edu.kz/jour/article/view/44

В данной работе отражены ингибиторы протонной помпы, которые на сегодняшний день относятся к наиболее часто назначаемым средствам в гастроэнтерологии, во всем мире. Влияние ИПП на тяжесть клинического течения COVID-19 инфекции у пациентов.Задача: Определить влияние ИПП на тяжесть клинического течения COVID-19 инфекции у пациентов.Влияние ИПП на восприимчивость к SARS-COV-2. Ингибиторы протонной помпы удваивают риск заражения коронавирусной инфекцией и являются одним из факторов заражения COVID-19.Анализ полученных данных показал, что использование ИПП связано с повышенным риском положительного теста на коронавирус, как уже отмечалось. По сравнению с респондентами, которые не используют эти препараты, у принимавших ИПП раз или два раза в день.

This work reflects proton pump inhibitors, which today are among the most commonly prescribed drugs in gastroenterology around the world. Impact of PPIs on the severity of the clinical course of COVID-19 infection in patients.Objective: To determine the effect of PPIs on the severity of the clinical course of COVID-19 infection in patients.The effect of PPIs on susceptibility to SARS-COV-2. Proton pump inhibitors double the risk of contracting coronavirus infection and area contributor to COVID-19 infection.Analysis of the data obtained showed that PPIs use is associated with an increased risk of a positive test for coronavirus, as already noted. Compared to respondents who do not use these drugs, those who used PPIs once or twice a day

Ингибиторы протонной помпыкоронавирусная инфекцияпантопразолрабепразолсоляная кислотариск зараженияproton pump inhibitorscoronavirus infectionpantoprazolerabeprazolehydrochloric acidrisk of infectionReferencesAby E.S., Rodin H., Debes J.D. Proton Pump Inhibitors and Mortality in Individuals With COVID-19. Am J. Gastroenterol. 2020 Nov;115(11):Aby E.S., Rodin H., Debes J.D. Proton Pump Inhibitors and Mortality in Individuals With COVID-19. Am J. Gastroenterol. 2020 Nov;115(11):Hajifathalian K., Katz P.O. Regarding "Increased Risk of COVID-19 in Patients Taking Proton Pump Inhibitors". Am J Gastroenterol. 2020 Nov;115(11):Hajifathalian K., Katz P.O. Regarding "Increased Risk of COVID-19 in Patients Taking Proton Pump Inhibitors". Am J Gastroenterol. 2020 Nov;115(11):Tarlow B., Gubatan J., Khan M.A., Cholankeril G. Are Proton Pump Inhibitors Contributing to SARS-COV-2 Infection? Am J Gastroenterol. 2020 Nov;115(11):Tarlow B., Gubatan J., Khan M.A., Cholankeril G. Are Proton Pump Inhibitors Contributing to SARS-COV-2 Infection? Am J Gastroenterol. 2020 Nov;115(11):Hadi Y.B., Naqvi S.F., Kupec J.T. Risk of COVID-19 in Patients Taking Proton Pump Inhibitors. Am J. Gastroenterol. 2020 Nov;115(11):Hadi Y.B., Naqvi S.F., Kupec J.T. Risk of COVID-19 in Patients Taking Proton Pump Inhibitors. Am J. Gastroenterol. 2020 Nov;115(11):da Rosa T.F., Foletto V.S., Serafin M.B., Bottega A., Hörner R. Anti-infective properties of proton pump inhibitors: perspectives. Int Microbiol. 2021 Sep 3:1-6.da Rosa T.F., Foletto V.S., Serafin M.B., Bottega A., Hörner R. Anti-infective properties of proton pump inhibitors: perspectives. Int Microbiol. 2021 Sep 3:1-6.Gubatan J., Zikos T., Spear Bishop E., Wu J., Gottfried A., Becker L., Habtezion A., Neshatian L. Gastrointestinal symptoms and healthcare utilization have increased among patients with functional gastrointestinal and motility disorders during the COVID-19 pandemic. Neurogastroenterol Motil. 2021 Aug 11: e14243.Gubatan J., Zikos T., Spear Bishop E., Wu J., Gottfried A., Becker L., Habtezion A., Neshatian L. Gastrointestinal symptoms and healthcare utilization have increased among patients with functional gastrointestinal and motility disorders during the COVID-19 pandemic. Neurogastroenterol Motil. 2021 Aug 11: e14243.Vaezi M.F., Yang Y.X., Howden C.W. Complications of proton pump inhibitor therapy. Gastroenterology 2017; 153:35–48.Vaezi M.F., Yang Y.X., Howden C.W. Complications of proton pump inhibitor therapy. Gastroenterology 2017; 153:35–48.Boushey H., Gonda I. Comment on Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors. Am J Gastroenterol. 2020 Nov;115(11):Boushey H., Gonda I. Comment on Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors. Am J Gastroenterol. 2020 Nov;115(11):Hodges P., Kelly P., Kayamba V. Helicobacter pylori infection and hypochlorhydria in Zambian adults and children: A secondary data analysis. PLoS One. 2021 Aug 27;16(8): e0256487.Hodges P., Kelly P., Kayamba V. Helicobacter pylori infection and hypochlorhydria in Zambian adults and children: A secondary data analysis. PLoS One. 2021 Aug 27;16(8): e0256487.Lo W.K., Chan W.W. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: A metaanalysis. Clin Gastroenterol Hepatol 2013; 11:483–90.Lo W.K., Chan W.W. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: A metaanalysis. Clin Gastroenterol Hepatol 2013; 11:483–90.Leonard J., Marshall J.K., Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102:2047–56; quiz 2057.Leonard J., Marshall J.K., Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102:2047–56; quiz 2057.Souza G., Zini N., de Andrade Gandolfi F., Muraro S.P., Luiz Proença-Modena J., Val F.A., Cardoso Melo G., Monteiro W.M., Nogueira M.L., Lacerda MVG, Moraes-Vieira P.M., Nakaya H.I. Acid pH Increases SARS-CoV-2 Infection and the Risk of Death by COVID-19. Front Med (Lausanne). 2021 Aug 20; 8:637885.Souza G., Zini N., de Andrade Gandolfi F., Muraro S.P., Luiz Proença-Modena J., Val F.A., Cardoso Melo G., Monteiro W.M., Nogueira M.L., Lacerda MVG, Moraes-Vieira P.M., Nakaya H.I. Acid pH Increases SARS-CoV-2 Infection and the Risk of Death by COVID-19. Front Med (Lausanne). 2021 Aug 20; 8:637885.Bavishi C., Dupont H.L. Systematic review: The use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011; 34:1269–81.Bavishi C., Dupont H.L. Systematic review: The use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011; 34:1269–81.

The authors declare that there are no conflicts of interest present.